# Bayesian hierarchical model for dose finding trial incorporating historical data

Linxi Han<sup>a</sup>, Qiqi Deng<sup>b,1</sup>, Zhangyi He<sup>c,2</sup>, Frank Fleischer<sup>d</sup>, Feng Yu<sup>\*,a</sup>

<sup>a</sup>School of Mathematics, University of Bristol, Bristol, United Kingdom <sup>b</sup>Biostatistics and Data Sciences, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, Connecticut,

USA

<sup>c</sup>Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK

<sup>d</sup>Biostatistics+Data Sciences Corp., Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany

# Abstract

The Multiple Comparison Procedure and Modelling (MCPMod) approach has been shown to be a powerful statistical tool that can significantly improve the design and analysis of dose finding studies under model uncertainty. Due to its frequentist nature, however, it is difficult to incorporate into MCPMod information from historical trials on the same drug. Recently, a Bayesian version of MCPMod has been introduced by Fleischer et al. (2022) to resolve this issue, which is particularly tailored to the situation where there is information about the placebo dose group from historical trials. In practice, information may also be available on active dose groups from early phase trials, e.g., a dose escalation trial and a preceding small Proof of Concept trial with only a placebo and a high dose. To address this issue, we introduce a Bayesian hierarchical framework capable of incorporating historical information about both placebo and active dose groups with the flexibility of modelling both prognostic and predictive between-trial heterogeneity. Our method is particularly useful in the situation where the effect sizes of two trials are different. Our goal is to reduce the necessary sample size in the dose finding trial while maintaining its target power.

<sup>\*</sup>Corresponding author.

*Email address:* feng.yu@bristol.ac.uk (Feng Yu)

<sup>&</sup>lt;sup>1</sup>Present address: 200 Technology Square Cambridge, MA 02139, United States

<sup>&</sup>lt;sup>2</sup>Present address: Cancer Research UK Beatson Institute, Glasgow G61 1BD, United Kingdom

*Key words:* Dose finding, Historical borrowing, Bayesian hierarchical framework, Between-trial heterogeneity

## 1 1. Introduction

A key component of successful pharmaceutical drug development is the accurate de-2 termination of an appropriate dose level in early phase clinical trials. The final selection 3 of dose level in Phase II studies has a considerable impact on the success probability of 4 confirmatory Phase III studies and consequently the entire drug development program. 5 Owing to the limited amount of available data on the efficacy and safety of a specific 6 compound and small sample sizes in early stages of clinical development, determining 7 the right dose level is among the most challenging steps during drug development. As 8 mentioned in Bretz et al. (2005), if the selected dose is too high, it can lead to safety 9 problems as well as unacceptable adverse events in later studies, while a too-low dose 10 leads to an increased likelihood that the drug fails to provide adequate clinical benefit, 11 which impacts success probabilities of trials in later phases. Hence, when we evaluate the 12 dose-response relationship, it is important to use a method capable of extracting the most 13 information from available data. A method based on a statistical model that accurately 14 reflects the clinical situation stands the best chance of yielding accurate estimates of the 15 dose-response relationship. 16

Traditionally, dose-finding trials have been addressed through either a multiple com-17 parison procedure (MCP) or a modelling (Mod) approach. Bretz et al. (2005) combined 18 these two approaches to devise an improved method called Multiple Comparison Pro-19 cedure and Modelling (MCPMod). The classic MCPMod assumes normally distributed 20 data. Pinheiro et al. (2014) extended the approach to non-normal data. The main idea 21 of MCPMod is to use a candidate set of parametric models to describe the unknown 22 dose-response relationship, test these candidate models against a flat curve using MCP 23 techniques and finally select a significant model to fit the data. This approach is rea-24 sonably robust against model misspecification since it allows the specification of multiple 25

candidate models that can hopefully cover all plausible dose-response relationships. It is
also flexible in the estimation of the optimal dose, which is not restricted to the doses
under investigation. European Medicines Agency (EMA) (2014) and USA Food and Drug
Administration (FDA) (2016) qualified MCPMod as an adequate and efficient method
for dose finding trials.

MCPMod is based on the frequentist methodology. As a result, it can be difficult for 31 a new study to incorporate information from historical trials on the same drug. Neuen-32 schwander et al. (2010) pointed out that information from historical trials can be im-33 portant to the design and analysis of a new trial. The incorporation of such historical 34 information in the design and analysis of a new study can reduce the duration of the 35 trial and/or the number of patients necessary to achieve the desired power, resulting in 36 a reduction of overall cost (Schmidli et al., 2014). There has been increasing interest in 37 incorporating such historical information into the design and analysis of clinical studies 38 (Berry, 2006). Existing methods to incorporating historical information includes power 39 priors (Ibrahim & Chen, 2000), meta-analytic analyses (Neuenschwander et al., 2010) 40 and commensurate priors (Hobbs et al., 2012). When incorporating historical data, it is 41 always desirable to design the framework in a way that is capable of modelling potential 42 differences between historical and current data. In view of this, these approaches discount 43 the information in the historical data to either a fixed degree or a degree determined dy-44 namically according to between-trial heterogeneity. 45

There has also been work that uses a Bayesian framework to include historical data 46 in the design and analysis of new trials. Fleischer et al. (2022) proposed an approach, 47 known as Bayesian MCPMod (BMCPMod), that focuses on the situation where such 48 historical information is coming only from the placebo dose group. BMCPMod essentially 49 reproduces the results of the classic MCPMod for non-informative priors but allows for 50 the incorporation of historical data if available, leading to an improvement in design 51 efficiency. However, in practice, historical information of active dose groups may also be 52 available from early phase trials, e.g., a dose-escalation trial and a preceding small Proof 53

<sup>54</sup> of Concept (PoC) trial with only a placebo and a high dose.

To address this problem, in this work we introduce a Bayesian hierarchical framework 55 for the dose finding problem. It incorporates historical information from both placebo 56 and active dose groups and accounts for both prognostic and predictive between-trial 57 heterogeneity. One of the primary use cases of this model is for cases where the effect 58 sizes of two trials are different. The goal is to reduce the necessary sample size in dose 59 finding trials while maintaining its target power. The Bayesian hierarchical model we 60 propose in this work performs the requisite analysis combining data from the two trials. 61 This is referred to as the meta-analytic-combined approach by Schmidli et al. (2014). 62

The remainder of this paper is structured as follows. In Section 2, we introduce our Bayesian hierarchical model and review the Bayesian pooling model. In Section 3, we perform simulation studies to compare these two approaches in terms of precision, power and type I error. Finally, Section 4 provides a summary and discussion of results.

#### 67 2. Methodology

#### 68 2.1. Bayesian hierarchical model

We assume there are two trials, a current trial and a historical trial, with  $\mathbf{Y}^{(c)}$  and  $\mathbf{Y}^{(h)}$  denoting the data from each trial, respectively. We also assume there are a total of K + 1 unique dose groups  $\mathcal{D} = \{d_0, ..., d_K\}$  in the two trials, including a placebo dose  $d_0$ . Let  $I_c$  and  $I_h$  denote the indices of doses present in the current and historical trial, respectively. Let  $n_i^{(c)}$  and  $n_i^{(h)}$  denote the number of patients from the current and/or historical trial, respectively, who are given dose  $d_i$ . For example, if  $i \notin I_c$ , then  $n_i^{(c)} = 0$ . We assume the following statistical model for  $\mathbf{Y}^{(c)}$  and  $\mathbf{Y}^{(h)}$ :

$$Y_{ij}^{(c)} \mid \mu_i, r \sim N\left(\mu_i + r, \sigma^2\right), i \in I_c, j = 1, \dots, n_i^{(c)}$$

$$Y_{ij}^{(h)} \mid \mu_i, a, r \sim N\left(a \cdot \mu_i - r, \sigma^2\right), i \in I_h, j = 1, \dots, n_i^{(h)}$$
(1)

where  $\mu_i = \mu(d_i)$  are the unknown mean effect of the treatment from the current trial at each dose level,  $\pm r$  denotes the deviation from the mean effect in each trial (as a

result of heterogeneity of prognostic effects), and a is a scalar to allow for heterogeneity in the predictive effects between the two trials. The mean effect  $\mu_i$  and the heterogeneity parameters r and a are assumed to be random. We will specify their prior distributions a bit later. We assume variance  $\sigma^2$  to be known and constant across all dose groups. The model can be easily extended to cases where the effect variance is not constant at different doses. Finally, we assume all  $Y_{ij}^{(c)}$  and  $Y_{ij}^{(h)}$  are conditionally independent given  $\mu_i$ , r and a.

For the mean effect  $\boldsymbol{\mu} = (\mu_0, \dots, \mu_K)$ , we use an improper non-informative uniform prior  $p(\mu_i) \equiv 1$  for all *i*. The heterogeneity of predictive effects (treatment effects) is represented by the fixed effect ratio *a* across different dose groups. The parameter *a* is assumed to be distributed as follows:

$$a \sim N(1, \eta^2) \text{ or } N_{[b, 1/b]}(1, \eta^2)$$
 (2)

where  $N_{[b,1/b]}$  denotes the normal distribution with variance  $\eta^2$  truncated to the interval [b, 1/b] for some 0 < b < 1. The heterogeneity of prognostic effects between the two trials is expressed by the random effect r with the following prior

$$r|\tau \sim N(0,\tau^2) \tag{3}$$

with between-trial standard deviation  $\tau$ . The parameter  $\tau$  controls the level of borrowing based on the similarity of prognostic effects between two trials. The prognostic effect under model (1) is  $2r + (1 - a)\mu_0$ , where  $\mu_0$  is the effect of the placebo dose.

<sup>95</sup> We give some intuition about the choice of the hyperparameter  $\tau$ . If  $\tau$  is close to <sup>96</sup> 0, then the assumption is that the prognostic heterogeneity is small between studies, <sup>97</sup> i.e. there is a small difference in response of the placebo arm between studies. On <sup>98</sup> the other hand, if  $\tau$  is large, then the prognostic heterogeneity between the trials is <sup>99</sup> high and the historical study data should have less relevance in the analysis of the data <sup>100</sup> from the current trial. To account for the uncertainty about  $\tau$ , we will use the half-

<sup>101</sup> normal prior distribution as its prior. This prior distribution should cover the range of <sup>102</sup> typical values representing plausible (e.g., from small to large) between-trial heterogeneity <sup>103</sup> (Spiegelhalter et al., 2004; Gelman, 2006; Röver et al., 2021). We will discuss the two types <sup>104</sup> of heterogeneities in Sections 2.4 and 2.5. Given an observed outcome  $\boldsymbol{Y} = (\boldsymbol{Y}^{(c)}, \boldsymbol{Y}^{(h)})$ , <sup>105</sup> the resulting posterior probability distribution for  $\boldsymbol{\mu}$ , a, r and  $\tau$  can be written as:

$$\mathbb{P}(\boldsymbol{\mu}, a, r, \tau \mid \boldsymbol{Y}) \propto \mathbb{P}(\boldsymbol{Y} \mid \boldsymbol{\mu}, a, r) \mathbb{P}(\boldsymbol{\mu}) \mathbb{P}(a) \mathbb{P}(r, \tau)$$

$$= \mathbb{P}(\boldsymbol{Y}^{(c)} \mid \boldsymbol{\mu}, r) \mathbb{P}(\boldsymbol{Y}^{(h)} \mid a, \boldsymbol{\mu}, r) \prod_{i=1}^{K} \mathbb{P}(\mu_i) \mathbb{P}(a) \mathbb{P}(r \mid \tau) \mathbb{P}(\tau),$$
(4)

106 where

$$\mathbb{P}(\boldsymbol{Y}^{(c)} \mid \boldsymbol{\mu}, r) = \prod_{i}^{I_{c}} \prod_{j}^{n_{i}^{(c)}} \mathbb{P}(Y_{ij}^{(c)} \mid \mu_{i}, r)$$
$$\mathbb{P}(\boldsymbol{Y}^{(h)} \mid a, \boldsymbol{\mu}, r) = \prod_{i}^{I_{h}} \prod_{j}^{n_{i}^{(h)}} \mathbb{P}(Y_{ij}^{(h)} \mid \mu_{i}, a, r).$$

<sup>107</sup> As the posterior probability distribution above is unavailable in a closed form, we <sup>108</sup> perform MCMC sampling using the Metropolis-Hastings algorithm to obtain posterior <sup>109</sup> samples of  $\mu$ , *a* and *r*. See Appendix A for details of this algorithm.

We recall that under the classic frequentist MCPMod, we would like to check for a non-flat relationship for the set of candidate models  $\mathcal{M} = \{M_m, m = 1, ..., M\}$ . We will define a Bayesian version of this test that corresponds to the null and alternative hypotheses, upon which we will assess type I error and power. Let  $\boldsymbol{c} = \{\boldsymbol{c}_1, ..., \boldsymbol{c}_m\}$  be the contrast vectors for the candidate models  $\mathcal{M}$  and  $\boldsymbol{\mu} = (\mu_1, ..., \mu_K)$  be the unknown mean effect vector of  $\mathcal{D}$ . For model m and its corresponding contrast vector  $\boldsymbol{c}_m$ , we consider the single model  $M_m$  to be significant at level  $\beta$  in our Bayesian sense if

$$\mathbb{P}(\boldsymbol{c}_m^T \boldsymbol{\mu} > 0 | \boldsymbol{Y}) > 1 - \beta.$$
(5)

As in the case of the classic MCPMod, the maximum of these probabilities across all

candidate models are considered in order to obtain our test decision. A significant doseresponse signal is established if

$$\max_{m \in \{1,...,M\}} \mathbb{P}(\boldsymbol{c}_m^T \boldsymbol{\mu} > 0 | \boldsymbol{Y}) > 1 - \beta.$$

The value of  $\beta$  needs to be picked so that type I error of the overall procedure is equal to the significance level  $\alpha$ , which is specified by the practitioner conducting the trial.

<sup>122</sup> Under classic MCPMod, the probability on the left hand side of (5) can be computed <sup>123</sup> numerically. This is, however, not feasible given the far more complicated model in our <sup>124</sup> Bayesian setting. But we can approximate this probability using the  $\mu$ -samples generated <sup>125</sup> using the MCMC procedure. If we have obtained a total of N samples  $\mu_1, \ldots, \mu_N$ , we <sup>126</sup> can simply compute  $c_m^T \mu_i$  for each i. We count the number of samples that produces a <sup>127</sup> positive  $c_m^T \mu_i$  and divide it by N, which we take to be our estimate of

$$\mathbb{P}(\boldsymbol{c}_m^T \boldsymbol{\mu} > 0 | \boldsymbol{Y}). \tag{6}$$

We summarise the procedure for checking the existence of non-flat relationship for the set of candidate models  $\mathcal{M}$ . This is the MCP part of the MCPMod. We fix a significance level  $\alpha$ , then we perform the following:

Step 1: Define a set of candidate models to represent the underlying true dose-response
shape, and derive the optimal contrast coefficients from each model based. This
step mirrors corresponding steps in MCPMod.

Step 2: Generate datasets of historical and current trials assuming the null model (i.e. flat dose responses). Estimate the threshold  $\beta$  using steps leading to (6) so that the desired type I error rate  $\alpha$  is achieved.

Step 3: With data  $\boldsymbol{Y}$ , test significance of each candidate model using (5) to assess whether a dose-response signal can be established. Proof of Concept (PoC) is established when at least one of the model tests is significant.

In this work, we focus on the MCP part of MCPMod. Given the  $\mu$ -samples we have generated for each candidate model in Step 3 above, we can perform the modelling part of the MCPMod using steps in the classic MCPMod. This is straightforward so we leave out the details.

## 144 2.2. Bayesian pooling model/ Bayesian model based on pooled data

An easy way to account for historical data is to simply pool the historical data with the current data, resulting in the pooled dataset  $\mathbf{Y}^{(p)}$ . We end up with a special case of the Bayesian hierarchical model described in Section 2.1, with r = 0,  $\mathbf{Y}^{(p)}$  replacing  $\mathbf{Y}^{(c)}$ , and the elimination of  $\mathbf{Y}^{(h)}$  and the parameter a. More specifically,  $Y_{ij}^{(p)}$  describes the variable of interest in patient j of dose group i and is assumed to be normally distributed

$$Y_{ij}^{(p)} \mid \mu_i \sim N(\mu_i, \sigma^2), i = 0, \dots, K, j = 1, \dots, n_i$$

where  $\mu_i$  are the unknown mean effect of the treatment and  $\sigma^2$  is assumed to be known. We follow the same steps as described in Section 2.1 to perform the MCP step. If  $\mu$  is given a non-informative prior, then the results obtained using our MCMC-based algorithm will converge to that of the classic MCPMod as the number of MCMC samples becomes large. We will compare our Bayesian hierarchical model with the Bayesian pooling model in Section 3.

#### 156 2.3. Choice of contrast vectors

In classic MCPMod, contrast vectors are chosen to maximise the probability of rejecting the null hypothesis when a candidate model is correct. MCPMod is relatively robust against non-optimal choice of contrast vectors. More specifically, even when the candidate model set does not contain the true underlying dose-response model, the probability of detecting a non-flat dose-response shape is not greatly affected in the MCP step, as long as a dose-response model with a shape similar to that of the true shape of dose-response model is included in the candidate set.

In Pinheiro et al. (2014), MCPMod is extended to allow for an estimated  $\hat{\mu}$ , which 164 can be estimated dose-response parameters using ANOVA or some other means. The 165 estimates  $\hat{\boldsymbol{\mu}}$  is assume to be distributed according to  $N(\boldsymbol{\mu}, \boldsymbol{S})$  where  $\boldsymbol{S}$  denotes the vari-166 ance/covariance of  $\hat{\mu}$ . The matrix **S** also needs to be estimated, producing  $\hat{S}$ , which can 167 be used to re-estimate the optimal contrast vectors. In our Bayesian setting, we use the 168 posterior samples of  $\mu$  to produce  $\hat{S}$ , which we use to re-estimate the optimal contrast 169 vectors. Compared to the optimal contrast vectors calculated from the regular MCPMod, 170 the re-estimated contrast vectors are data dependent and adjust the weight on difference 171 dose groups automatically. For example, it will reduce the weight on doses where the 172 posterior variance is large. As we will see in Section 3, this can improve the performance 173 of our algorithm in certain cases. 174

We will use contrast vectors calculated according to the classic MCPMod as well as contrast vectors re-estimated using the posterior distribution in later simulation studies.

# 177 2.4. Heterogeneity of prognostic effects

In (1), heterogeneity of prognostic effects between different trials, which is defined 178 to be independent of effects of treatment, is primarily accounted for by r. Generally 179 speaking, when we design a clinical study, we typically have some prior information 180 about how similar this study is to a historical study. This is usually assessed based 181 on the similarity of key factors that could impact the response, for example, the target 182 study populations, the regions of the site, and the formulation or delivery route of the 183 intervention, etc. In our setting, as described in (3), we impose a normal prior with 184 mean 0 and standard deviation  $\tau$ . We impose a half-normal hyperprior on  $\tau$ . Following 185 Neuenschwander et al. (2010), we adopt  $0.5\sigma$  as the standard deviation of the half-186 normal distribution. According to Friede et al. (2017),  $0.5\sigma$  is sufficient to capture typical 187 heterogeneity values seen in meta-analyses of heterogeneous studies, making it a sensible 188 choice in many applications. The sensitivity analyses for different levels of heterogeneity 189 prior will be discussed in Appendix E. Although we use a half-normal distribution here, a 190 more flexible distribution could also be considered, e.g., half-T, half-Cauchy, Gamma or 191

Inverse Gamma distributions (Spiegelhalter et al., 2004; Gelman, 2006; Polson & Scott,
2012).

# <sup>194</sup> 2.5. Heterogeneity of predictive effects

In (1), the parameter a serves to model heterogeneity of predictive factors between 195 different trials. It describes the difference in treatment effect sizes between studies. The 196 maximum effect in the historical study is a times the one in the current study. Typically, 197 predictive factors have a greater influence on the results of analysis than prognostic 198 factors. As described in (2), we impose a normal prior distribution (truncated under some 199 circumstances) on a, with mean 1 and between-trial heterogeneity standard deviation  $\eta$ . 200 When  $\eta = 0$  and a = 1, we have the same effect size between the historical and current 201 trials, which means that there is no between-trial heterogeneity and therefore all data 202 from two studies can be pooled for the analysis. The standard deviation  $\eta$  in the prior 203 can be used to adjust the strength of prior information on a. We recommend plausible 204 values of a to be inside the interval  $[1 - \eta, 1 + \eta]$ , i.e. within one standard deviation of 205 the mean 1. 206

We truncate the prior distribution for a to an interval [b, 1/b] for some 0 < b < 1 if 207  $\boldsymbol{Y}^{(c)}$  and  $\boldsymbol{Y}^{(h)}$  do not have exactly the same doses, i.e. there are doses that are present 208 in one but the other trial. The reason for this is because in these cases, the posterior 209 estimates for a are more unstable, thereby needing slightly more prior information to 210 prevent a from becoming negative, which we deem as unrealistic. When we truncate the 211 normal distribution, we typically pick b to be around 1/3, since it is unlikely that two 212 trials differ in treatment effect size by a factor of more than 3. We do not recommend 213 taking b to be very close to 0, as it leads to the simulated posterior distribution a to be 214 concentrated at 0, resulting in non-convergence of the simulated posterior distribution of 215 treatment effects of dose groups. We find the choice b = 1/3 gives robust results under 216 our approach. 217

A log-normal distribution can also be used as the prior distribution of *a*. Since this distribution samples only positive values, its performance is similar to that of the truncated

220 normal distribution.

#### 221 3. Simulation studies

## 222 3.1. Simulation design

To evaluate the performance of our method, we run simulation studies. We take 223  $\mathcal{D}_c = \{0, 0.15, 0.5, 0.8, 1\}$ , i.e. there are K = 4 active doses with a placebo dose in the 224 current study. In the historic study, we consider two scenarios as described in Table 1a, 225 with 4 and 5 doses that overlaps those in the current study. We standardise the doses 226 and take the standard deviation to be 1. We take the true placebo response rate to be 0 227 and the maximal response to be 0.5. In what follows, we only consider equal allocation, 228 i.e., each dose group contains 40 patients, 200 patients in total in the current study. We 229 specify M = 6 different location-scale models in the candidate model set  $\mathcal{M}$ , as shown 230 in Figure 1. 231



Figure 1: Visualisation of the candidate model set in the simulations.

Dose finding process in early stage usually contains a series of clinical trials for different purposes, including dose escalation trial, proof of concept (PoC) trial and dose-ranging

trial. The Phase I dose escalation trial is usually the first time when a new drug is applied 234 to humans. Such trial usually increases the doses of an investigational drug by cohorts, 235 until an upper limit is reached, which is usually defined by the maximum tolerable dose. 236 Sometimes it can also be based on a maximum feasible dose by formulation and delivery, or 237 pharmacological active dose where the signal indicating the desired pharmacological effect 238 is achieved. Although Phase I dose escalation trials are typically conducted in healthy 239 volunteers and the efficacy data is not available, there are cases where the Phase I dose 240 escalation trials need to be done in patients. Examples include investigating drugs for 241 renal impaired patients where their PK profile will be different from healthy volunteers, 242 or for drugs that may be toxic and cannot ethically be applied to healthy volunteers. 243 After Phase I, a PoC needs to be established in early Phase II to make a Go/No-Go 244 decision based on the efficacy performance. If the new drug demonstrates the efficacy, 245 the concept is considered proven, leading to a Phase IIb dose-ranging trial. Therefore, a 246 new dose-ranging trial can borrow historical information from a dose escalation trial or a 247 PoC trial. In our simulation studies, we consider two scenarios: two dose escalation trials 248 with different settings, as shown in Table 1a. We also consider an additional scenario 249 (Phase IIa PoC trial) in Appendix D. 250

To evaluate the robustness of our method, we run three one-sided hypothesis tests in 251 each scenario, which are summarised in Table 1b. Scenario A assumes the effect size of 252 the historical trial is worse than the effect size of the current trial. The null hypothesis 253 states that the treatment effect at each dose was the same as the placebo dose, and 254 the alternative hypothesis states that at least one dose group has a positive treatment 255 effect. Scenario B assumes that the treatment effect size of the historical trial exceeds the 256 current trial. Definitions of the null and alternative hypotheses are the same as scenario 257 A. In scenarios A and B, the results of the historical and current trials are basically 258 homogeneous. The drug either worked in both trials or did not work in either. 259

In scenario C, however, we consider an extreme case of large discrepancies between the
 historical and the current trial. In scenarios A and B, the null and alternative hypotheses

			Number of
Scenario	Source	Dose set	overlapping doses
1	Phase I dose escalation trial	$\mathcal{D}_h = \{0, 0.15, 0.5, 0.8, 1\}$	5
2	Phase I dose escalation trial	$\mathcal{D}_h = \{0, 0.1, 0.5, 0.8, 1\}$	4

Two scenarios of historical trial. Dose set of current trial  $\mathcal{D}_c$ (a) =  $\{0, 0.15, 0.5, 0.8, 1\}.$ 

Scenario		$\Delta_c$	$\Delta_h$
A Null hypothesis Alternative hypothesis B	$H_0^m : \mathbf{c}_m^T \boldsymbol{\mu} = 0$ $H_1^m : \mathbf{c}_m^T \boldsymbol{\mu} > 0$	$\begin{array}{c} 0 \\ 0.5 \end{array}$	$\begin{array}{c} 0 \\ 0.3 \end{array}$
Null hypothesis Alternative hypothesis C	$H_0^m : \mathbf{c}_m^T \boldsymbol{\mu} = 0$ $H_1^m : \mathbf{c}_m^T \boldsymbol{\mu} > 0$	$\begin{array}{c} 0 \\ 0.3 \end{array}$	$\begin{array}{c} 0 \\ 0.5 \end{array}$
Null hypothesis Alternative hypothesis	$H_0^m : \mathbf{c}_m^{(c)T} \boldsymbol{\mu} = 0$ $H_0^m : \mathbf{c}_m^{(c)T} \boldsymbol{\mu} > 0$	$\begin{array}{c} 0 \\ 0.5 \end{array}$	$0.3 \\ 0.3$

(b) Three hypothetical scenarios in simulation study.  $\Delta_c =$  true effect size of current trial;  $\Delta_h$  = true effect size of historical trial;  $a = \Delta_h / \Delta_c$ ;  $\mathbf{c}_m^{(c)}$  = contrast vector of current trial (elements of dose groups in historical trial only are zeros).

Table 1: Simulation scenarios.

are built on the current and historical trials, but in scenario C, the null and alternative 262 hypotheses are built on the current study only. More specifically, we take 263

$$\mathbf{c}_m^{(c)} = \begin{cases} \mathbf{c}_m & \text{if } m \in \mathcal{D}_c \\ 0 & \text{otherwise} \end{cases}$$

i.e. the test statistic does not take into account responses at doses not present in the 264 current study. This scenario may arise from a situation where it is known that the drug 265 has an effect in the historical trial and we investigate a new indication or population to 266 find out whether the drug has an effect in the new trial. Differences in patient populations 267 or other trial-specific circumstances can lead to large heterogeneity among historical trials 268 and between the current trial and historical trials. In each scenario, we investigate four 269 different levels of prognostic heterogeneity between the historical and current trials. 270

For each scenario, to assess the power to detect model m from the candidate model 271

set  $\mathcal{M}$ , we simulate datasets assuming model m to be the true dose-response curve. The data is generated according to the treatment effect that is assumed under the alternative hypothesis for the computation of power, or according to the null hypothesis for type I error computation. The steps for estimating power and type I error of our algorithm are shown in Appendix B.

As described in Section 2.4, a half-normal prior with standard deviation 0.5 (i.e., HN(0.5)) is used for the between-study standard deviation of prognostic effects across scenarios A, B and C, and a truncated normal distribution with mean 1 and standard deviation 0.4 (i.e.,  $N_{[1/3,3]}(1,0.4^2)$ ) is assigned for the effect ratio *a*. To compare our Bayesian hierarchical model (BHM), we also perform

a pooled Bayesian analysis that includes the data of all trials without accounting for
 between-trial heterogeneity,

284 2. an MCPMod analysis of only the current trial.

We use the Receiver Operating Characteristic (ROC) curve (Bradley, 1997; Fawcett, 2006) to evaluate and compare operating characteristics from different approaches. An ROC curve plots the True Positive Rate (TPR) (sensitivity), also known as power, against the False Positive Rate (FPR) (i.e., 1 – specificity), also known as type I error. In this paper, we plot ROC curves for FPR  $\in [0.025, 0.1]$ , which is a reasonable type I error range for dose finding trials.

# 291 3.2. Simulation results

#### 292 3.2.1. Scenario 1

Here we consider a phase I dose escalation trial, where all dose groups in the historical trial are the same as those in the current trial, each with the same known variance and sample size. In Table 2a, we summarise powers achieved using various approaches at 5% type I error rate for the candidate model set illustrated in Figure 1. Amongst these approaches is MCPMod (full borrowing), where we simply pool data from both the historical and current studies to which we apply the classic MCPMod method. We

show the corresponding ROC curves in Figure 4. For all dose groups, the type I error is calculated with a true flat dose-response curve with response 0, and the power is calculated with a true non-flat dose-response curve.

We see from Table 2a and Figure 4 that MCPMod (no borrowing) yields the worst 302 performance from the four approaches, which should be expected since borrowing from 303 historical information can boost the power. MCPMod (full borrowing) and the Bayesian 304 pooling model (BPM) have almost the same performance. In comparison, BHM yields 305 better performance than all other approaches. This implies that modelling the between-306 trial heterogeneity can further improve the performance, i.e., BPM simply combines the 307 historical and current trials into a single trial, but BHM discounts the historical infor-308 mation according to the between-trial heterogeneity. Note that here we use the optimal 309 contrast vector derived from MCPMod rather than the re-estimated contrast vector, but 310 these two contrasts are shown to reveal similar behaviours. 311

In the following, we will only focus on the analysis of the linear model. The other five models are expected to exhibit similar behaviour. The main purpose of the simulation study is to identify in each scenario which methods have good power. We generate data with four different levels of heterogeneity in prognostic factor effects, r = 0, 0.1, 0.2, 0.3, respectively. For each scenario, we estimate the treatment effect size of the current study, which is the mean of 10,000 posterior means of  $\mu_5$ . This is shown in Table 2b.

Figure 2 compares the ROC curve of BHM and BPM as a function of  $FPR \in$ 318 [0.025, 0.1] for four cases with different heterogeneities of prognostic factor under sce-319 nario 1A, 1B and 1C. We see that the ROC curves of BPM under scenarios 1A and 1B 320 look similar to each other. This is because the treatment effect size of the pooled trial 321 is the average effect size of two trials, hence BPM is mainly influenced by the average 322 treatment effect of two trials. For BPM, since the prognostic factor effect r has opposite 323 signs in the historical and current trials, different levels of heterogeneity in prognostic 324 factor effects have no influence on the results, so that similar patterns of results are ob-325 served across four different values of r. Table 2b shows that BHM produces more accurate 326

Approach	Linear	Emax1	Emax2	Exponential	Quadratic	Logistic
MCPMod no borrowing	0.7901	0.7916	0.7752	0.7638	0.6793	0.8681
MCPMod full borrowing	0.8759	0.8763	0.8650	0.8579	0.7839	0.9356
BPM	0.8710	0.8705	0.8651	0.8563	0.7744	0.9334
BHM	0.8964	0.8983	0.8951	0.8902	0.8185	0.9493

(a) Power values for MCPMod (no borrowing), MCPMod (full borrowing), Bayesian pooling model (BPM) and Bayesian hierarchical model (BHM) for the candidate model set when controlling type I error at 5%. Note that the simulation error can be estimated using binomial error as  $\sqrt{\frac{p(1-p)}{n}}$  where p is the power value at 5% type I error and n is number of simulations. BHM = Bayesian hierarchical model; BPM = Bayesian pooling model.

Scenario	Model	r  = 0	r  = 0.1	r  = 0.2	r  = 0.3
Scenario 1A					
Null hypothesis		r = 0	r = 0.1	r = 0.2	r = 0.3
$(\Delta_c = \Delta_h = 0)$	BHM	0.0004	0.0027	0.0020	0.0016
	BPM	0.0010	-0.0006	0.0015	0.0023
Alternative hypothesis		r = 0	r = 0.1	r = 0.2	r = 0.3
$(\Delta_c = 0.5, \ \Delta_h = 0.3)$	BHM	0.4766	0.4782	0.4856	0.4892
	BPM	0.4010	0.4019	0.4005	0.3971
Scenario 1B					
Null hypothesis		r = 0	r = -0.1	r = -0.2	r = -0.3
$(\Delta_c = \Delta_h = 0)$	BHM	0.0011	-0.0007	0.0009	0.0012
	BPM	0.0001	-0.0004	0.0016	-0.0007
Alternative hypothesis		r = 0	r = -0.1	r = -0.2	r = -0.3
$(\Delta_c = 0.3, \ \Delta_h = 0.5)$	BHM	0.3828	0.3799	0.3752	0.3720
	BPM	0.4002	0.4118	0.4011	0.3993
Scenario 1C					
Null hypothesis		r = 0	r = 0.1	r = 0.2	r = 0.3
$(\Delta_c = 0, \ \Delta_h = 0.3)$	BHM	0.1157	0.1273	0.1201	0.1175
	BPM	0.1509	0.1492	0.1458	0.1483
Alternative hypothesis		r = 0	r = 0.1	r = 0.2	r = 0.3
$(\Delta_c = 0.5, \ \Delta_h = 0.3)$	BHM	0.4718	0.4805	0.4863	0.4876
	BPM	0.3992	0.4011	0.3998	0.4009

(b) Mean estimated treatment effect size under three simulation scenarios with four different levels of prognostic heterogeneity.  $\Delta_c$  = effect size of current trial;  $\Delta_h$  = effect size of historical trial. This table displays mean estimates of  $\Delta_c$ .

Table 2: Scenario 1.



Figure 2: The ROC curves of MCPMod, Bayesian pooling model (BPM) and Bayesian hierarchical model (BHM) with four different levels of prognostic heterogeneity for scenario 1. The dashed grey line denotes 5% false positive rate, i.e., 5% type I error rate.

estimates of the effect size as the value of r increases. This is probably due to the prior 327 HN(0.5) we use for the prognostic between-trial heterogeneity standard deviation rep-328 resenting a large prognostics heterogeneity. Even though the bias becomes smaller with 329 the increase of the value of r, the ROC curves of BHM look similar to each other for all 330 four different values of r, as can be seen from Figure 2. The sensitivity analysis of the 331 results for prognostic heterogeneity will be discussed in Appendix E. 332

Under scenarios 1A and 1C, the ROC curve of BHM is always above the ROC curve 333 of BPM, but under scenario 1B, BPM performs better than BHM. We surmise this is due 334

to the fact that under scenario 1B where the effect size of the historical trial is higher than the current trial, BHM largely discounts the impact of historical data on the basis of observed divergence when incorporating historical information, leading to reduced power values. Even though BHM's ROC curve is below that of BPM under scenario 1B, the estimates of the effect size under BHM is more accurate.

With BPM, when the treatment effect size in the new trial is worse than that in the historical trial, the borrowing of historical information leads to overestimates of treatment effects across the active dose groups. Thus it leads to higher power but that comes at the cost of type I error inflation. Generally speaking, we would prefer to use BHM to perform dynamic borrowing where the amount of historical data borrowed is related to the agreement between the current and historical trial.

When historical treatment effect size differs from the current trial, BPM may not reflect the true treatment effect size. On the other hand, the posterior mean estimates of the true effect size using BHM has smaller bias. Compared to BPM, BHM is a better statistical analysis method that can reasonably boost statistical power while controlling type I error.

#### 351 3.2.2. Scenario 2

Here we investigate a scenario where there is at least one non-overlapping dose between the historical and the current trial. In scenario 2, the current trial has a dose of 0.15 but not 0.1, and the historical trial has a dose of 0.1 but not 0.15. The existence of non-overlapping doses has an influence on both BPM and BHM.

Table 3 displays the estimated treatment effects of dose groups 0.1 and 0.15 under scenarios A, B and C. Apparently BHM produces more accurate estimates for these two dose groups, i.e. with smaller bias, than BPM. For both BHM and BMP, larger magnitudes in the level of prognostic heterogeneity r produces larger biases in the estimates.

Figure 3 displays ROC curves of both BHM and BPM, using both the initial contrast of MCPMod as well as re-estimated contrasts. Unlike in Scenario 1, we see that both BHM and BPM performs better if we use re-estimated contrast. We will focus on perfor-



Figure 3: The ROC curves of MCPMod, Bayesian pooling model (BPM) and Bayesian hierarchical model (BHM) with four different levels of prognostic heterogeneity for scenario 2.

mance using re-estimated contrasts in the subsequent discussion. If there is no prognostic 363 heterogeneity (i.e., r = 0), we find BHM to have mixed performance compared to that 364 of BPM, sometimes better, sometimes worse. Indeed, when r = 0, the pooling model is 365 the correct model, but this is not the case if  $r \neq 0$ . Therefore we see the advantage of 366 BHM over BPM tends to increase as the level of prognostic heterogeneity increases. This 367 is caused by a decrease in the power of BPM as r increases, while the power of BHM 368 holds roughly steady. When type I error is controlled at 5%, the power of BPM went 369 from 0.8833 for r = 0 to 0.8614 for r = 0.3. 370

As mentioned earlier, we use re-estimated contrast vector in this scenario, not the initial contrast vector derived from MCPMod which would lead to some power loss. Figure 5 displays boxplots of the estimated treatment effects of six dose groups for BPM and BHM. The estimates for the second and third doses, both of which only exists in one of the two trials, has larger variability. Results from scenarios 2A, 2B and 2C show similar effect. Therefore, it is beneficial to apply a re-estimation step based on the covariance matrix  $\hat{S}$  after each MCMC simulation to derive a re-estimated contrast vector.

Under scenario 2C, we consider two decision rules to detect a significant PoC. The 378 first one is using all of dose groups in current and historical trials (decision rule I) and the 379 second one is using dose groups in the current trial only (decision rule II). The third row 380 of Figure 3 compares the performance of BPM and BHM using these two decision rules. 381 It shows that the ROC curve of BHM is above that of BPM with either decision rule. 382 This is not surprising since BHM produces much more accurate estimates than BPM 383 under scenario 2C, as shown in Table 3. We observe that BHM has better performance 384 when using decision rule II as the dose found only in the historical trial is ignored. This 385 indicates that even though we use a re-estimated contrast vector, the performance is also 386 influenced by the non-overlapping doses. On the other hand, the ROC curve of BPM 387 is higher with decision rule I than decision rule II. Therefore, when there exist non-388 overlapping doses between the historical and current trials, we recommend using decision 389 rule II when the data is pooled. 390

# <sup>391</sup> 4. Discussion

In this paper, we proposed a Bayesian hierarchical model for dose finding trials that incorporates information from historical trials. The model can take into account both prognostic and predictive between-trial heterogeneities. We detailed how to set up a Bayesian multiple comparison procedure, how to choose contrast vectors, and how to check for a non-flat dose response given a desired type I error  $\alpha$ . We evaluated the performance of our model and illustrated the utility of our approach through three simulation medRxiv preprint doi: https://doi.org/10.1101/2022.03.12.22272175; this version posted March 14, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Scenario	Model	r  = 0	r  - 0.1	r  - 0.2	r  - 0.3
Scenario 24	mouel	'  = 0	'  = 0.1	'  = 0.2	'  = 0.0
Null hypothesis		r = 0	r = 0.1	r = 0.2	r = 0.3
$0.10 (\mu = 0)$	внм	7 = 0 0.0058	7 = 0.1	7 = 0.2	7 = 0.0
$0.10 \ (\mu_2 = 0)$	BDIIM BDM	0.0035	-0.0200	-0.0247	-0.0209
0.10(u = 0)		0.0055	-0.1010	-0.2000	-0.3013
$0.10 \ (\mu_3 = 0)$		0.0005	0.0108	0.0139 0.1076	0.0121
Altornativo hypothosis	DFM	0.0022 r = 0	0.1004 r = 0.1	0.1970 r = 0.2	0.5052 r = 0.3
Alternative hypothesis $0.10 (\mu_{\rm c} - 0.030)$	внм	7 = 0	7 = 0.1	7 = 0.2	7 = 0.3
$0.10 \ (\mu_2 = 0.050)$		0.0220	-0.0204	-0.0328	-0.0375
0.15(0075)		0.0285	-0.0714	-0.1705	-0.2081
0.15 ( $\mu_3 = 0.075$ )	DDM	0.0820	0.0980	0.1019	0.1012
	BPM	0.0807	0.1735	0.2725	0.3720
Scenario 2B		0	0.1	0.0	0.0
Null hypothesis	DING	r = 0	r = -0.1	r = -0.2	r = -0.3
$0.10 \ (\mu_2 = 0)$	BHM	0.0403	0.0255	0.0241	0.0258
	BPM	0.0043	0.1021	0.2147	0.2975
$0.15 \ (\mu_3 = 0)$	BHM	0.0004	-0.0174	-0.0159	-0.0095
	BPM	0.0046	-0.1127	-0.1965	-0.3110
Alternative hypothesis		r = 0	r = -0.1	r = -0.2	r = -0.3
$0.10 \ (\mu_2 = 0.050)$	BHM	0.0519	0.0661	0.0683	0.0722
	BPM	0.0507	0.1528	0.2439	0.3517
$0.15 \ (\mu_3 = 0.045)$	BHM	0.0407	-0.0294	-0.0650	-0.0803
	BPM	0.0450	-0.0547	-0.1525	-0.2526
Scenario 2C					
Null hypothesis		r = 0	r = 0.1	r = 0.2	r = 0.3
$0.10 \ (\mu_2 = 0.030)$	BHM	0.0292	-0.0310	-0.0402	-0.0414
() _	BPM	0.0276	-0.1288	-0.2276	-0.3318
$0.15 \ (\mu_3 = 0)$	BHM	0.0010	0.0307	0.0526	0.0757
() 5 )	BPM	-0.0003	0.0963	0.2006	0.2988
Alternative hypothesis		r = 0	r = 0.1	r = 0.2	r = 0.3
$0.10 \ (\mu_2 = 0.030)$	BHM	0.0220	-0.0264	-0.0328	-0.0375
\/ <del>-</del> /	BPM	0.0283	-0.0714	-0.1705	-0.2681
$0.15 \ (\mu_3 = 0.075)$	BHM	0.0820	0.0980	0.1019	0.1012
- (r-0	BPM	0.0807	0.1735	0.2725	0.3726

Table 3: Estimated treatment effect of two non-overlapping doses under three simulation scenarios with four different levels of prognostic heterogeneity. This table displays mean estimates of  $\mu_2$  or  $\mu_3$ . BHM = Bayesian hierarchical model; BPM = Bayesian pooling model.

studies, in comparison with the Bayesian pooling model, where data from both trials are 398

pooled. 399

The main advantage of Bayesian hierarchical model lies in scenarios where there is a 400 measurable difference between the behaviour of the historical and the new trials. Com-401

pared to the Bayesian pooling model, the Bayesian hierarchical model produces more 402 accurate estimates of the treatment effects in our simulation studies, even when the ef-403 fect sizes are different in the two trials. We used heavy-tailed hyperpriors for prognostic 404 heterogeneity and truncated normal priors for predictive heterogeneity so that the results 405 were not sensitive to the prior distribution. Even with an inappropriate prior distribu-406 tion, power usually does not differ too much, hence power values should not be strongly 407 affected by prior-data conflicts. We provide more details on effects of prior-data conflicts 408 in Appendix E. 409

One key limitation of our approach is that we assumed a fixed effect ratio across dif-410 ferent doses, which implies that a fixed relationship between the current and historical 411 trials regardless of dose. In practice, however, this may not hold. This assumption can be 412 relaxed and our approach can be extended to handle this situation, but extended model 413 will have a larger number of unknown parameters. Our method under the assumption 414 of a fixed effect ratio across different doses may be a good trade-off between model com-415 plexity and generality. Furthermore, in this work, we only consider the case of borrowing 416 information from one historical dose finding trial. Our method can be easily extended to 417 cases where information from multiple historical trials or parallel trials can be borrowed. 418

#### 419 References

<sup>420</sup> Berry, D. A. (2006). Bayesian clinical trials. *Nature Reviews Drug Discovery*, 5, 27–36.

- Bradley, A. P. (1997). The use of the area under the ROC curve in the evaluation of
  machine learning algorithms. *Pattern Recognition Letters*, 30, 1145–1159.
- Bretz, F., Pinheiro, J. C., & Branson, M. (2005). Combining multiple comparisons and
  modeling techniques in dose-response studies. *Biometrics*, 61, 738–748.
- European Medicines Agency (EMA) (2014). Qualification Opinion of MCPMod as an efficient statistical methodology for model-based design and analysis of Phase II dose finding studies under model uncertainty. https:

- 428 //www.ema.europa.eu/en/documents/regulatory-procedural-guideline/
- qualification-opinion-mcp-mod-efficient-statistical-methodology-model-based-designen.pdf.
- Fawcett, T. (2006). An introduction to ROC analysis. Pattern Recognition Letters, 27,
  861–874.
- Fleischer, F., Bossert, S., Deng, Q., Loley, C., & Gierse, J. (2022). Bayesian MCPMod. *Pharmaceutical Statistics*, doi:10.1002/pst.2193.
- Friede, T., Röver, C., Wandel, S., & Neuenschwander, B. (2017). Meta-analysis of two
  studies in the presence of heterogeneity with applications in rare diseases. *Biometrical Journal*, 59, 658–671.
- Gelman, A. (2006). Prior distributions for variance parameters in hierarchical models.
  Bayesian Analysis, 1, 515–534.
- Hobbs, B. P., Sargent, D. J., & Carlin, B. P. (2012). Commensurate priors for incorporating historical information in clinical trials using general and generalized linear models. *Bayesian Analysis*, 7, 639–674.
- Ibrahim, J. G., & Chen, M.-H. (2000). Power prior distributions for regression models.
  Statistical Science, 15, 46–60.
- Neuenschwander, B., Capkun-Niggli, G., Branson, M., & Spiegelhalter, D. J. (2010).
  Summarizing historical information on controls in clinical trials. *Clinical Trials*, 7, 5–18.
- Pinheiro, J., Bornkamp, B., Glimm, E., & Bretz, F. (2014). Model-based dose finding
  under model uncertainty using general parametric models. *Statistics in Medicine*, 33,
  1646–1661.
- <sup>451</sup> Polson, N. G., & Scott, J. G. (2012). On the half-Cauchy prior for a global scale param<sup>452</sup> eter. *Bayesian Analysis*, 7, 887–902.

- <sup>453</sup> Röver, C., Bender, R., Dias, S., Schmid, C. H., Schmidli, H. et al. (2021). On weakly
  <sup>454</sup> informative prior distributions for the heterogeneity parameter in Bayesian random<sup>455</sup> effects meta-analysis. *Research Synthesis Methods*, 12, 448–474.
- <sup>456</sup> Schmidli, H., Gsteiger, S., Roychoudhury, S., O'Hagan, A., Spiegelhalter, D. et al. (2014).
- 457 Robust meta-analytic-predictive priors in clinical trials with historical control informa-
- 458 tion. *Biometrics*, 70, 1023–1032.
- 459 Spiegelhalter, D. J., Abrams, K. R., & Myles, J. P. (2004). Bayesian Approaches to
- 460 Clinical Trials and Health-care Evaluation. Chichester: John Wiley & Sons.
- <sup>461</sup> USA Food and Drug Administration (FDA) (2016). Statistical review and evaluation
- qualification of statistical approach: MCP-Mod. https://www.fda.gov/downloads/
- <sup>463</sup> Drugs/DevelopmentApprovalProcess/UCM508701.pdf.

# <sup>464</sup> A. Metropolis-Hasting algorithm

465 For each time step t, our algorithm consists of the following steps:

466 Step 1: Generate a proposal sample  $\boldsymbol{\theta}^{\text{cand}} = (\boldsymbol{\mu}^{\text{cand}}, a^{\text{cand}}, r^{\text{cand}}, \tau^{\text{cand}})$  from the pro-467 posal distribution  $q(\boldsymbol{\theta}^t | \boldsymbol{\theta}^{t-1});$ 

468 Step 2: Compute the acceptance probability via the acceptance function

$$A\left(\boldsymbol{\theta}^{\text{cand}} \mid \boldsymbol{\theta}^{(t-1)}\right) = \min\left\{1, \frac{p\left(\boldsymbol{\theta}^{t} \mid \boldsymbol{Y}\right)q\left(\boldsymbol{\theta}^{t} \mid \boldsymbol{\theta}^{t-1}\right)}{p\left(\boldsymbol{\theta}^{t-1} \mid \boldsymbol{Y}\right)q\left(\boldsymbol{\theta}^{t-1} \mid \boldsymbol{\theta}^{t}\right)}\right\}$$

based on the proposal distribution and the joint density function (4).

470 Step 3: Accept the candidate sample with probability A, i.e. take  $\boldsymbol{\theta}^{t-1} = \boldsymbol{\theta}^{\text{cand}}$ . Other-471 wise, reject the candidate sample and take  $\boldsymbol{\theta}^{t-1} = \boldsymbol{\theta}^{t-1}$ .

These steps are repeated until a sufficient number of posterior samples have been gener-ated.

We run 500,000 MCMC iterations for each replicate. We discard the first 5,000 iterations as burn-in and then thin the remaining output by keeping every tenth observation.

# 476 B. Steps for estimating power

469

The steps for estimating power of our algorithm for fixed values of a, r and  $\alpha$  are as follows:

479 Step 1: repeat the following steps 10000 times:

480 1a. Generate  $\mathbf{Y}^{(c)}$  and  $\mathbf{Y}^{(h)}$  assuming model m to be flat, using (1).

<sup>481</sup> 1b. Repeat steps of Metropolis-Hastings (MH) algorithm described above until a <sup>482</sup> sufficient number of samples of the parameters  $\mu$  have been obtained.

- 483 1c. Calculate the probability  $\max_{m \in 1,...,M} \mathbb{P}(\boldsymbol{c}_m^T \boldsymbol{\mu} > 0 | \boldsymbol{Y}).$
- Step 2: use points with a spacing of 0.0001 from 0 to 1 as thresholds to estimate type I errors (i.e.,  $\max_{m \in 1,...,M} \mathbb{P}(\boldsymbol{c}_m^T \boldsymbol{\mu} > 0 | \boldsymbol{Y}) > c$ , for  $c \in [0, 1]$ ) and choose a specific threshold  $\alpha$  such that the desired type I error 5% is achieved.

487 Step 3: repeat the following steps 10000 times:

- 488 3a. Generate  $\mathbf{Y}^{(c)}$  and  $\mathbf{Y}^{(h)}$  assuming model m to be true, using (1).
- 489 3b. Repeat steps of Metropolis-Hastings (MH) algorithm described above until a 490 sufficient number of samples of the parameters  $\mu$  have been obtained.
- 491 3c. Calculate the probability  $\max_{m \in 1,...,M} \mathbb{P}(\boldsymbol{c}_m^T \boldsymbol{\mu} > 0 | \boldsymbol{Y}).$
- Step 4: use the obtained threshold  $\alpha$  in Step 2 and count how many times the test decision is significant (i.e.,  $\max_{m \in 1,...,M} \mathbb{P}(\boldsymbol{c}_m^T \boldsymbol{\mu} > 0 | \boldsymbol{Y}) > 1 - \alpha$ ), this proportion of simulations for which the null hypothesis is rejected is the estimate of the power of the test.

# 496 C. Figures

# 497 C.1. Figure for scenario 1



Figure 4: The ROC curves of MCPMod, Bayesian pooling model (BPM) and Bayesian hierarchical model (BHM) across six candidate models for scenario 1A.



Figure 5: Boxplot of estimated treatment effects across different doses of Bayesian hierarchical model (BHM) and Bayesian pooling model (BPM) under scenario 2A.

#### C.2. Figure for scenario 2 498

#### D. Scenario 3: a phase II PoC trial 499

Scenario 3 is a phase II PoC trial, where two high doses are compared to a placebo 500 dose (i.e.,  $\mathcal{D}_h = \{0, 0.8, 1\}$ ). We run our method with same settings as in Section 3. 501 Table 4 displays power across six candidate models when type I error is controlled at 502 5%. We generate the response data under six dose-response models in Figure 1 as the 503 true underlying dose-response model without prognostic heterogeneity (r = 0). We apply 504 three methods, including MCPMod (no borrowing), BPM (pooling) and BHM (dynamic 505 borrowing), to the dataset under scenario 3A. Both BPM and BHM result in a higher 506 power than the no borrowing model for all of six candidate models. Under 5 of the 507 6 dose-response models, BHM outperforms BPM. The only exception is the quadratic 508 model. The ROC curves of six candidate models are shown in Figure 6. 509

Figure 7 shows the ROC curves of MCPMod, BPM and BHM with four levels of 510 prognostic heterogeneity for scenario 3. Results and finding for BHM under scenario 3 511 are similar to scenarios 1 and 2. However, the behaviour of BPM is different from scenarios 512 1 and 2. Under scenarios 3A and 3C, as the level of prognostic heterogeneity increases, 513



Figure 6: The ROC curves of MCPMod (no borrowing), Bayesian pooling model (BPM) and Bayesian hierarchical model (BHM) across six candidate models for scenario 3A.

Approach	Linear	Emax1	Emax2	Exponential	Quadratic	Logistic
MCPMod no borrowing	0.7901	0.7916	0.7752	0.7638	0.6793	0.8681
BPM	0.8517	0.8711	0.8777	0.8309	0.7930	0.9022
BHM	0.8884	0.8915	0.8936	0.8588	0.7665	0.9278

Table 4: Power values for MCPMod (no borrowing), Bayesian pooling model (BPM) and Bayesian hierarchical model (BHM) for the candidate model set when controlling type I error at 5%.

the ROC curve of BPM lower significantly indicating that it is more sensitive to the 514 heterogeneity of prognostic effects. Table 5 shows the estimated treatment effects of non-515 overlapping dose groups. It shows BHM produces a much smaller bias in the treatment 516 effect estimates across nearly all scenarios and level of prognostic heterogeneity only has 517 little influence on the treatment effect estimates. On the other hand, BPM produces a 518 large bias in the treatment effect estimates of non-overlapping dose groups and as the 519 level of prognostic heterogeneity increases, there is an obvious increase in bias under all 520 scenarios. There is a large bias in the estimated treatment effects of non-overlapping 521 dose groups using BPM. These two non-overlapping dose groups are in the current trial 522

medRxiv preprint doi: https://doi.org/10.1101/2022.03.12.22272175; this version posted March 14, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Scenario	Model	r  = 0	r  = 0.1	r  = 0.2	r  = 0.3
Scenario 3A		1 1		1 1	1 1
Null hypothesis		r = 0	r = 0.1	r = 0.2	r = 0.3
$0.15 \ (\mu_2 = 0)$	BHM	0.0014	0.0150	0.0219	0.0228
(1 2 )	BPM	0.0023	0.1000	0.1996	0.2994
$0.50 \ (\mu_3 = 0)$	BHM	0.0015	0.0182	0.0177	0.0252
(75)	BPM	0.0006	0.1033	0.1988	0.3024
Alternative hypothesis		r = 0	r = 0.1	r = 0.2	r = 0.3
$0.15 \ (\mu_2 = 0.075)$	BHM	0.0737	0.0987	0.1098	0.1119
(1 2 )	BPM	0.0713	0.1738	0.2738	0.3702
$0.50 \ (\mu_3 = 0.250)$	BHM	0.2541	0.2730	0.2879	0.2873
() 0	BPM	0.2504	0.3525	0.4484	0.5511
Scenario 3B					
Null hypothesis		r = 0	r = -0.1	r = -0.2	r = -0.3
$0.15 \ (\mu_2 = 0)$	BHM	0.0014	0.0150	0.0219	0.0228
() - /	BPM	0.0023	0.1000	-0.1996	-0.2994
$0.50 \ (\mu_3 = 0)$	BHM	0.0015	0.0182	0.0177	0.0252
(10)	BPM	0.0006	-0.1033	-0.1988	-0.3024
Alternative hypothesis		r = 0	r = -0.1	r = -0.2	r = -0.3
$0.15 \ (\mu_2 = 0.045)$	BHM	0.0960	0.0829	0.0812	0.0791
() - )	BPM	0.0437	-0.0578	-0.1510	-0.2551
$0.50 \ (\mu_3 = 0.150)$	BHM	0.1999	0.1937	0.1934	0.1902
	BPM	0.1526	0.0513	-0.0473	-0.1554
Scenario 3C					
Null hypothesis		r = 0	r = 0.1	r = 0.2	r = 0.3
$0.15 \ (\mu_2 = 0)$	BHM	-0.0012	0.0290	0.0576	0.0796
() - /	BPM	0.0045	0.0991	0.2010	0.3010
$0.50 \ (\mu_3 = 0)$	BHM	0.0010	0.0307	0.0526	0.0757
(10)	BPM	0.0013	0.0964	0.1979	0.2960
Alternative hypothesis		r = 0	r = 0.1	r = 0.2	r = 0.3
$0.15 \ (\mu_2 = 0.075)$	BHM	0.0737	0.0987	0.1098	0.1119
·· /	BPM	0.0713	0.1738	0.2738	0.3702
$0.50 \ (\mu_3 = 0.250)$	BHM	0.2541	0.2730	0.2879	0.2873
	BPM	0.2504	0.3525	0.4484	0.5511

Table 5: Estimated treatment effect of two non-overlapping dose groups under three simulation scenarios with four different levels of prognostic heterogeneity. BHM = Bayesian hierarchical model; BPM = Bayesian pooling model.

<sup>523</sup> only, which means that when the effect size of the current trial is larger than that in the <sup>524</sup> historical trial, BPM overestimates the treatment effects of these two dose groups. In <sup>525</sup> contrast, when the effect size of the current trial is smaller than that in the historical trial, <sup>526</sup> BPM underestimates the treatment effect of these two dose groups. Under scenario 3B,



Figure 7: The ROC curves of MCPMod, Bayesian pooling model (BPM) and Bayesian hierarchical model (BHM) with four different levels of prognostic heterogeneity for scenario 3.

Figure 7 shows that the gap between ROC curves of BPM and BHM increase significantly 527 as the prognostic heterogeneity increases. The power values at 5% type I error for BPM 528 increases gradually from 0.8682 for r = 0 to 0.9616 for r = 0.3. The optimal contrast 529 coefficients of these two dose groups for the linear dose-response curve are negative. But 530 the estimates of  $\mu_2$  and  $\mu_3$  under the alternative hypothesis have the wrong sign. This 531 leads to an increase in the power of BPM. 532

In summary, our simulation studies show that BHM can estimate treatment effects of 533 each dose group more accurately than BPM when there exists heterogeneity of prognostic 534

effects, especially for non-overlapping dose groups, resulting in higher statistical power for fixed type I error.

#### 537 E. Prior-data conflicts

For the historical trial, there is usually a reasonable amount of information from internal or external company databases, literature and expert opinions that can be used to formulate an appropriate prior of prognostic and predictive heterogeneities. There may exist a mismatch observed between the prior and the data. For this purpose this section will investigate the impact of prior-data conflicts on the performance of BHM under scenarios 1A, 2A and 3A.

We will first discuss prior-data conflict of heterogeneity of prognostic effects. We 544 assume that information on prognostic factors from the current and historical trials can be 545 constructed as informative hyperpriors. In the following simulations, we fix the standard 546 deviation of prior of the effect size a at  $\eta = 0.4$  and generate data from two extreme 547 values of r = 0 and r = 0.5. For the heterogeneity of prognostic effects, we consider 548 five half-normal prior distributions with scales 0.0625, 0.125, 0.25, 0.5 and 1.0 for the 549 prognostic between-study standard deviation  $\tau$ . These specifications include up to small, 550 moderate, substantial, large and very large heterogeneity, respectively. 551

Scale of half-normal	1	0.5	0.25	0.125	0.0625
prior distribution	T	0.0	0.20	0.120	0.0025
r = 0					
Scenario 1A	0.4821	0.4854	0.4815	0.4991	0.5013
Scenario 2A	0.4912	0.4913	0.4997	0.4997	0.5009
Scenario 3A	0.4638	0.4645	0.4766	0.4868	0.4946
r = 0.5					
Scenario 1A	0.4912	0.4913	0.5067	0.5152	0.5273
Scenario 2A	0.4952	0.5017	0.5118	0.5203	0.5287
Scenario 3A	0.4920	0.5052	0.5190	0.5249	0.5291

Table 6: Estimated treatment effect size using different scales of half-normal prior distribution for three scenarios. The true effect size is 0.5 ( $\Delta_c = 0.5$ ).

Table 6 summarises effect size estimates using half-normal prior distribution with

Scale of half-normal	1	0.5	0.25	0.195	0.0625
prior distribution	1	0.0	0.20	0.120	0.0025
r = 0					
Scenario 1A	0.8891	0.8917	0.8905	0.8935	0.8943
Scenario 2A	0.8853	0.8879	0.8851	0.8859	0.8893
Scenario 3A	0.8689	0.8769	0.8806	0.8831	0.8864
r = 0.5					
Scenario 1A	0.8816	0.8922	0.8899	0.8892	0.8835
Scenario 2A	0.8831	0.8905	0.8831	0.8827	0.8773
Scenario 3A	0.8701	0.8769	0.8699	0.8667	0.8614

Table 7: Power values at 5% type I error using different scales of half-normal prior distribution for three scenarios.

five different scales. Generally speaking, when the scale of half-normal distribution is 553 approximately equal to the value of prognostic effect r, incorporating historical data on 554 the treatment effect leads to little bias in the estimate. For example, in the case of 555 r = 0, effect size estimates using scale 0.0625 were more accurate than other scales. 556 This is because more accurate hyperparameters for the hyper priors are used resulting 557 in more accurate effect size estimates for the current trial. The scale of the half-normal 558 distribution exceeding the value of prognostic effect will result in overestimates the effects 559 size with increasing bias as the level of prognostic heterogeneity increases. 560

Table 7 shows power values for the linear model of the candidate model set using 561 half-normal distribution with five levels of prognostic heterogeneity in the hyperprior for 562 the between-trial standard deviation  $\tau$ . When there is no prior-data conflict, the effect 563 size can be estimated more accurately using the appropriate prior distribution, resulting 564 in higher power. In contrast, as the discrepancy between the true prognostic effect of the 565 data and the prior increases, so does the probability of prior-data conflict, which can lead 566 to increases in bias and losses in power. However, power values of half-normal prior dis-567 tribution with different scales differ slightly, the difference between the maximum power 568 and the minimum power is approximately only 0.1. Using heavy-tailed distributions as 569 hyperpriors has the advantage of ensuring some degree of robustness against prior mis-570 specification, reducing the effects of prior-data conflicts. Even if the historical trial is 571

similar to the current study in their specification, we believe that prior-data conflict may still occur because of additional unanticipated factors. In such situations we recommend using weakly informative half-normal priors HN(0.5) that captures heterogeneity values typically seen in meta-analyses of heterogeneous studies and will therefore be a sensible choice in many applications.

<sup>577</sup> Next, we consider the prior-data conflict for the heterogeneity of predictive effects. <sup>578</sup> As discussed in Section 2.5, the choice of the value of the standard deviation  $\eta$  is critical. <sup>579</sup> In these simulations, we use HN(0.5) as the prior of prognostic between-heterogeneity <sup>580</sup> standard deviation  $\tau$  and generate data from r = 0. For the heterogeneity of treatment <sup>581</sup> effects (i.e., the effects ratio *a*), we consider truncated normal distribution with the same <sup>582</sup> mean 1 and seven values of standard deviation  $\eta$ .

Value of $\eta$	0.1	0.2	0.3	0.4	0.5	1	2	pooling
Scenario 1A	0.4097	0.4390	0.4796	0.4998	0.5072	0.5367	0.5458	0.4020
Scenario 2A	0.4112	0.4439	0.4803	0.5014	0.5108	0.5228	0.5284	0.3201
Scenario 3A	0.4074	0.4262	0.4621	0.4831	0.4936	0.5240	0.5322	0.3975

Table 8: Estimated treatment effect size using different standard deviations of truncated normal prior distribution for three scenarios. The true effect size is 0.5 ( $\Delta_c = 0.5$ ).

Value of $\eta$	0.1	0.2	0.3	0.4	0.5	1	2	pooling
Scenario 1A	0.8732	0.8845	0.8895	0.8936	0.8891	0.8873	0.8849	0.8753
Scenario 2A	0.8803	0.8829	0.8894	0.8916	0.8897	0.8841	0.8789	0.8828
Scenario 3A	0.8492	0.8605	0.8672	0.8832	0.8762	0.8705	0.8694	0.8461

Table 9: Power values at 5% type I error using different standard deviations of truncated normal prior distribution for three scenarios.

Table 9 contains power values for the linear model of the candidate set using seven standard deviations for the prior distributions. Considering the seven prior distributions an impact of the prior-data conflict can be observed. From Table 8 we can see that estimated effect size using BHM is similar to BPM if a lower standard deviation ( $\eta = 0.1$ ) is used for the prior of a. This prior distribution ( $TN(1, 0.1^2)$ ) represents a situation where we would intuitively consider there is prior-data conflict, because under this prior, the true value of the effect size (a = 0.6) cannot be covered, leading to lower power values. In

the case of a too high standard deviation (e.g.,  $\eta = 2$ ) there is no longer a benefit through 590 the use of BHM. This is because weakly informative prior distributions should have little 591 influence on the posterior distribution and therefore on the Bayesian inference. As shown 592 in Table 8, we see that values of 0.3, 0.4, 0.5 and 1 have higher power than BPM in all 593 scenarios and the power is higher when the value of  $\eta$  is set to 0.4. As mentioned in Section 594 2.5, the value of  $\eta$  can be estimated roughly using the empirical rule and this rule states 595 that 68% of the distribution will occur within one standard deviation. Under scenario A, 596 the true value of effect ratio a is equal to 0.6 and a prior distribution  $TN(1, 0.4^2)$  has 68% 597 of its observations within one standard deviation of the mean 1 (i.e.,  $1 \pm \eta$ ), which means 598 the probability that a variable is within a range [0.6, 1.4] in this normal distribution is 599 68%. Since this prior distribution is symmetric the standard deviation  $\eta = 0.4$  is also an 600 optimal choice for a = 1.4. We recommend using this approach to determine the value 601 of standard deviation  $\eta$ . 602

In the case of no reliable information for the effect ratio, the prior distribution needs to 603 be suitably vague so that it includes the unexpected, e.g.  $\eta = 0.5$  and  $\eta = 1$ . There exists 604 several appropriate choices of the standard deviation. Even though the inappropriate 605 choice of the prior distribution is selected, the power usually do not differ too much 606 that means power values should not be strongly affected by prior-data conflicts. This 607 is due to weakly informative truncated normal prior distributions used in our model. 608 This truncated normal prior distribution with a truncation range [1/3, 3] provides better 609 robustness than a normal distribution. A value of the effect ratio a exceeds this range 610 corresponds to extremely large heterogeneity of treatment effects, and would essentially 611 lead to no borrowing from the historical trial. 612

Therefore, heavy-tailed hyperpriors for prognostic heterogeneity and truncated normal priors for predictive heterogeneity imply a degree of robustness against prior-data conflicts which means the results are not sensitive to the prior specification. Even though the inappropriate choice of the prior distribution is selected, the power usually do not differ too much that means power values should not be strongly affected by prior-data conflicts.